Biopharma

#Biopharma #Carbon emissions #Environmental impact #Sustainability

Survey reveals biopharma sustainability lacks momentum

In the Global Biopharma Sustainability Review by Cytiva, more than 800 pharma and biopharma professionals articulated the benefits of meeting sustainability targets – and the risks of not clearly measuring progress on those targets. The research includes insights from executives in 18 countries. Sustainability is rising… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Automated workflows #Automation #Automation / robotics #Biopharma #Biopharmaceuticals #Data science #Drug development #Drug discovery #Lab automation #Lab technology #Personalised medicine #Pharmaceuticals

New podcast: How technology is impacting drug discovery

This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI is critical to solving new complexities in drug discovery and… Read More

#News

Medical researchers
#Association of the British Pharmaceutical Industry #Biopharma #Career #Pharmaceutical industry

Why is Gen-Z choosing to work in pharma?

Younger workers in the UK are increasingly choosing careers in pharmaceuticals over other industries like technology or finance due to perceptions of better work life balance and social purpose in the sector. This is according to a new report ‘Young people’s perceptions of careers in the… Read More

#News

Protein
#Biopharma #Cryo-EM #Drug discovery #Molecular Biology #Protein degradation

How targeted protein degradation will live up to the hype 

Dr Benedict Cross, CTO, PhoreMost, explores the drug discovery potential that targeted protein degradation (TPD) offers.   The ubiquitin proteasome pathway (UPP) has been a subject of interest for therapeutic intervention since the first proteasome inhibitors to treat multiple myeloma were developed and approved in 2015. The targeted recruitment of… Read More

#Exclusive Content

#Biopharma #Clinical trials #Contract Research Organisations (CROs)

Q&A: What attracted Moderna’s Co-founder to the board of Lindus Health?

Earlier this year, Robert S. Langer, Co-founder of Moderna and MIT Professor, made the decision to join the advisory board of Lindus Health, a company labelling itself as an anti-contract research organisation (CRO) and which is dedicated to running faster and more reliable trials for the life sciences industry.  … Read More

#Exclusive Content

#Biopharma #Biopharmaceuticals #GlobalData #Market reporting

Biopharma industry optimistic about growth in the next year

The biopharmaceutical industry is revealing increasing optimism regarding its growth prospects over the next 12 months. While the upward trend is a positive sign, it remains below the levels of confidence seen in 2022, finds data and analytics company GlobalData. In a recent survey, ‘The State of the Biopharmaceutical Industry 2024… Read More

#Business & Investment #News

Target concept
#Biopharma #Covid-19 #Drug discovery

The value of mission-orientated research in biopharma R&D 

Patrick Speedie, Co-Founder & Co-CEO of IN-PART, explores why a global approach is needed for the best science to prosper and the lessons industry can take from the Covid-19 pandemic.    The Covid-19 pandemic unequivocally demonstrated the power of industry-academia collaboration, with the fastest ever development, testing and approval of a… Read More

#Exclusive Content

#Biomanufacturing #Biopharma #Cancer therapeutics #Drug discovery #Immutep #LAG-3

New podcast: Important therapies for the future of immunotherapy

This is the latest episode of the free DDW narrated podcast, “Important therapies for the future of immunotherapy”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Improving quality control for CAR T cell therapies”, and… Read More

#News

#Assay #Biologics / Biotechnology #Biopharma #Diversity #DNA #Drug development #Drug discovery #Gene sequencing #Ingredients / APIs / Fine chemicals #Synthetic biology #Women in Discovery #Women in STEM

New podcast: Overcoming different barriers in drug discovery

This is the latest episode of the free DDW narrated podcast, “Overcoming different barriers in drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Addressing the challenge of salt forms in drug discovery”, “… Read More

#News

#ABPI #Big pharma #Biopharma #Covid-19 #Ipsos #UK

Pharma maintains high level of trust from UK public and doctors

The pharmaceutical industry continues to maintain strong levels of public trust and favourability in the UK, according to data from the Association of the British Pharmaceutical Industry (ABPI). Opinions showed consistent recognition of the sector’s support for the NHS, with 67% of respondents saying the industry… Read More

#News

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News

#Biopharma #Cell line development #Cell lines #FDA #Genetic diseases #Genetics #R&D

New podcast: Challenges and tactics for drug development

This is the latest episode of the free DDW narrated podcast, “Challenges and tactics for transformative drug development”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Balancing speed and quality in CLD for faster drug development”, and… Read More

#News

#Biopharma #Biotech #Clarivate #Collaboration #Investment #Partnership

Biopharma investment drops by nearly 50% in 2022

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The report combines data and… Read More

#Business & Investment #News #Trends & Analysis

San Diego Conference Centre
#Automation #Biopharma #Drug discovery #SLAS2023

Highlights from SLAS2023: Day One

The first full day of SLAS2023 offered plenty for visitors to see and learn from. Here are some of the biggest launches that were on offer throughout day one of the show. PerkinElmer targets screening methods End-to-end solutions provider PerkinElmer launched two new products at the show targeting both high… Read More

#News

#Automated workflows #Automation #Automation / robotics #Biopharma #Biopharmaceuticals #Lab automation #Lab technology #Personalised medicine

The push towards lab automation in biopharma

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Peter Walters, Director Advanced Therapies, CRB, and Grace Linton, Director Process Architecture, CRB about automation within laboratory settings and its effect on the pharmaceutical industry. RA: How are labs utilising automated systems in regard to personalised medicines?… Read More

#Exclusive Content

#AI #Biopharma #Biopharmaceuticals #Comment #DNA #Lab automation #SLAS2022 #Synthetic biology

Podcast: The impact of synthetic biology and collaboration in pharma

This is the latest episode of the free DDW podcast. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Why synthetic biology is the next big thing for biopharma” and “Collaborative spirit helps drive innovation”. ‘Can synthetic biology save… Read More

#News